心血管

订阅

MedSci主页 / 所有栏目 / 心血管

一种新的冠心病风险评估方法获美批准

2014-12-17 小田 译 医学论坛网

冠心病风险评估方法Lp-PLA2
关注

美国食品与药物管理局(FDA)近日批准了可评估血浆脂蛋白相关的磷脂酶A2(Lp-PLA2)筛选检测法用于评估目前无冠状动脉性心脏病(CHD)的CHD风险和冠状动脉粥样硬化人群的卒中风险。 这种检测方法名为PLAC检测，是一种特定的血管炎性酶，可用于预测女性CHD风险，尤其是非裔美国女性人群。 FDA是基于“卒中地理和种族差异的原因”亚组研究结果批准该种检测方法的。该研究纳入了459

美国食品与药物管理局(FDA)近日批准了可评估血浆脂蛋白相关的磷脂酶A2(Lp-PLA2)筛选检测法用于评估目前无冠状动脉性心脏病(CHD)的CHD风险和冠状动脉粥样硬化人群的卒中风险。

这种检测方法名为PLAC检测，是一种特定的血管炎性酶，可用于预测女性CHD风险，尤其是非裔美国女性人群。

FDA是基于“卒中地理和种族差异的原因”亚组研究结果批准该种检测方法的。该研究纳入了4598例年龄45岁至92岁的目前无CHD的受试者。在中位随访5年后，那些Lp-PLA2水平>225 nmol/min/mL的个体CHD事件发生率为7.0%，而那些<225 nmol/min/mL 的个体这种事件发生率则为3.3%。当Lp-PLA2>225 nmol/min/mL时，黑人女性的CHD事件发生率显著升高。因此，PLAC检测说明书含有单独的黑人男性和女性、白人男性和女性的工作数据。

英文链接：FDA Approves Lp-PLA2 Test for Patients Without Existing Coronary Disease




您还可以这样阅读，更多资讯，请关注MedSci微信
  

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1770976, encodeId=f80f1e7097699, content=<a href='/topic/show?id=5572308336a' target=_blank style='color:#2F92EE;'>#冠心病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30833, encryptionId=5572308336a, topicName=冠心病风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc938196115, createdName=hbwxf, createdTime=Sat Nov 28 05:37:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059104, encodeId=a1b120591049a, content=<a href='/topic/show?id=45c5914864a' target=_blank style='color:#2F92EE;'>#评估方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91486, encryptionId=45c5914864a, topicName=评估方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Sep 19 15:37:00 CST 2015, time=2015-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14323, encodeId=cdbf14323d3, content=可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Wed Jan 14 16:36:00 CST 2015, time=2015-01-14, status=1, ipAttribution=)]
    2015-11-28 hbwxf

    #冠心病风险#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1770976, encodeId=f80f1e7097699, content=<a href='/topic/show?id=5572308336a' target=_blank style='color:#2F92EE;'>#冠心病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30833, encryptionId=5572308336a, topicName=冠心病风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc938196115, createdName=hbwxf, createdTime=Sat Nov 28 05:37:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059104, encodeId=a1b120591049a, content=<a href='/topic/show?id=45c5914864a' target=_blank style='color:#2F92EE;'>#评估方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91486, encryptionId=45c5914864a, topicName=评估方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Sep 19 15:37:00 CST 2015, time=2015-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14323, encodeId=cdbf14323d3, content=可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Wed Jan 14 16:36:00 CST 2015, time=2015-01-14, status=1, ipAttribution=)]
    2015-09-19 智慧医人

    #评估方法#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1770976, encodeId=f80f1e7097699, content=<a href='/topic/show?id=5572308336a' target=_blank style='color:#2F92EE;'>#冠心病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30833, encryptionId=5572308336a, topicName=冠心病风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc938196115, createdName=hbwxf, createdTime=Sat Nov 28 05:37:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059104, encodeId=a1b120591049a, content=<a href='/topic/show?id=45c5914864a' target=_blank style='color:#2F92EE;'>#评估方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91486, encryptionId=45c5914864a, topicName=评估方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Sep 19 15:37:00 CST 2015, time=2015-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14323, encodeId=cdbf14323d3, content=可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Wed Jan 14 16:36:00 CST 2015, time=2015-01-14, status=1, ipAttribution=)]
    2015-01-14 MedSci客户端网友

    可以

    0